11/7/2007

The FDA rejected Novartis AG's and Momenta Pharmaceuticals' follow-on version of the anti-clotting drug Lovenox because of concerns about the treatment's possible effect on the immune system. Momenta CEO Craig Wheeler said the FDA could ask that Momenta conduct additional clinical trials of the drug.

Related Summaries